Kathy Johnson Weiler Buys Shares of Axogen, Inc.
Kathy Johnson Weiler purchased 14,150 shares of Axogen, Inc. on June 19, 2026.
Key Points
- On June 19, 2026, Kathy Johnson Weiler bought 14,150 shares of Axogen, Inc., showing insider confidence.
- Axogen, Inc. shares traded near $44.95 on Wednesday, with a market cap of $2.39 billion and a 52-week high of $45.83.
- Analysts maintain a positive outlook, with firms like Canaccord Genuity and Wells Fargo setting a buy rating and targets around $50.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Kathy Johnson Weiler made a notable insider purchase of Axogen, Inc. shares on June 19, 2026. She acquired 14,150 shares of the company, which trades on the Nasdaq Capital Market under the ticker AXGN. This move highlights insider confidence in the company's prospects.
Insider Buying and Selling at Axogen, Inc.
Several insiders, including Kathy Johnson Weiler, made purchases on June 19, 2026. Each insider, including Amy McBride Wendell, Alan Levine, Paul Thomas, and Joseph Tyndall, bought 14,150 shares, while Paul Thomas acquired an additional 18,867 shares. These transactions were not part of any pre-planned trading program, indicating a direct decision to invest in the company.
Axogen, Inc. Stock Down 13.2%
Shares of NasdaqCM:AXGN traded near $44.95 on Wednesday. Axogen, Inc. has a market cap of approximately $2.39 billion. It operates in the healthcare sector, specifically within medical devices. The stock has experienced a 52-week low of $9.35 and a high of $45.83, with a 50-day moving average of $40.43 and a 200-day moving average of $30.40. The company has a forward P/E ratio of 61.72 and a beta of 1.118, reflecting its volatility relative to the market.
$AXGN stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on Axogen, Inc. On April 29, 2026, firms such as Canaccord Genuity, Citizens, Wells Fargo, and HC Wainwright & Co. reiterated their 'buy' ratings, with price targets around $50. Lake Street also maintained a 'buy' rating with a similar target on April 23, 2026. The consensus among nine analysts suggests a target mean price of approximately $50.78.
About Axogen, Inc.
Axogen, Inc., headquartered in Alachua, Florida, specializes in the development and commercialization of technologies for peripheral nerve regeneration and repair. The company offers products like the Avance Nerve Graft and Axoguard Nerve Connector, which are used in surgical repairs. Led by CEO Michael D. Dale, Axogen employs 622 people and provides its products to hospitals and surgery centers worldwide.
Bottom Line
Kathy Johnson Weiler's recent purchase of Axogen shares underscores a strong insider belief in the company's future. As Axogen continues to develop its niche in peripheral nerve repair, investors and analysts alike are watching closely. The insider activity, coupled with a maintained 'buy' rating from multiple analysts, suggests a positive sentiment surrounding Axogen's growth potential.
Get Axogen, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AXGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.